3
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Cervical ripening with oral prostaglandin E2 tablets and the effect of the latent period in patients with premature rupture of the membranes at term

, &
Pages 405-408 | Published online: 02 Jul 2009
 

Summary

A prospective, random allocation study was performed to assess the effect of the length of the latent period and the efficacy of oral prostaglandin E2 tablets for induction of labour in women with premature rupture of the membranes at term.

Forty-nine women were allocated to early induction of labour (group 1) and 48 to delayed induction (group 2). The median interval from rupture of the membranes to induction was 3–25 hours in group I and 200 hours in group 2. The median interval from rupture of the membranes to delivery was 13–5 hours in group 1 compared to 22–9 hours in group 2. There was no difference between the two groups with respect to gestational age, birth weight and mode of delivery. Twenty-four hours after admission all of group 1 women were delivered compared to only 58 per cent of group 2 women. There were no statistical differences in the incidences of maternal or neonatal infective morbidity between the two groups.

These observations suggest that there is no advantage to a prolonged latent period and that oral prostaglandin E2 tablets are effective in the induction of labour in these patients.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.